Clinical Trial Update: Diurnal Variation of Plasminogen Activator Inhibitor-1 [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining diurnal variation of plasminogen activator inhibitor-1 (PAI-1) in people with metabolic syndrome. The study results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Metabolic Syndrome X | Phase 4 | Status: COMPLETED | Results posted: 2019-02-01